Trial · NCT07203053
A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2
NCT07203053, Phase 2, Recruiting, ETOP IBCSG Partners Foundation
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2. Trials, record NCT07203053. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07203053
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2
- NCT number
- NCT07203053
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 48 participants, estimated
- Lead sponsor
- ETOP IBCSG Partners Foundation
- Conditions
- Extensive Stage Lung Small Cell Cancer
- Interventions
- Tarlatamab
- First posted
- 2025-10-02
- Last updated
- 2026-09-21
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall survival rate at 12 months (12-month OS) | OS is defined as the time from the date of enrolment until death from any cause. Assessed for approximately up to 41 months. | The OS rate at 12 months is the primary endpoint of the trial. It is defined as the proportion of patients who are alive at 12 months from enrolment. The rate will be calculated as the number of patients alive at 12 months divided by the number of patients on follow-up at 12 months or with an earlier observed death event. |
| Secondary | Objective response rate (ORR) | Assessed for approximately up to 41 months. | Objective response rate (ORR) is defined as the rate of patients, among all those enrolled, who achieve a best overall response \[complete response (CR) or partial response (PR)\] according to the RECIST v1.1 across all post-enrolment time-points until the end of follow up for disease progression. |
| Secondary | Duration of response (DoR) | Assessed for approximately up to 41 months. | Duration of response (DoR) is defined as the time from the date of first documentation of objective response (CR or PR according to RECIST v1.1) to the date of first documented progression or death. Censoring will occur at the last tumour assessment with response other than progression. Patients without tumour assessment after documented objective response will be censored at the date of documented objective response (plus 1 day). |
| Secondary | Disease control rate (DCR) | Assessed for approximately up to 41 months. | Disease control rate (DCR) is defined as the rate of patients, among all those enrolled, who achieve CR or PR according to RECIST v1.1 or stabilisation of disease (SD), lasting for at least 12 weeks. |
| Secondary | Progression-free survival (PFS) | Assessed for approximately up to 41 months. | Progression-free survival (PFS) is defined as the time from the date of enrolment until documented progression (according to RECIST v1.1) or death if progression is not documented. Censoring (for patients without documented progression or death) will occur at the date of last tumour assessment. Patients without a post-baseline tumour assessment will be censored at the date of enrolment (plus 1 day). |
| Secondary | Incidence, nature, and severity of adverse events | Assessed for approximately up to 41 months. | Incidence, nature, and severity of adverse events according to CTCAE v5, except for CRS and ICANS, that are graded according to the ASTCT criteria21 and TLS that are graded according to the Cairo-Bishop classification All safety parameters will be summarised in tables to evaluate the toxicity/safety profile of the protocol treatment based on: * Adverse events (AEs) according to CTCAE v5.0 (any-cause as well as treatment-related) including AEs leading to dose delays and/or interruptions, withdrawal of protocol treatment, and death. * Occurrence of CRS and ICANS, defined according to the American Society for Transplantation and Cellular Therapy (ASTCT) criteria published by Lee et al. (2019). * Occurrence of TLS, defined according to the Cairo-Bishop classification.22 * Severe and serious AEs. * Laboratory parameters and abnormalities, and vital signs. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07203053
GET https://conductscience.org/api/trials/v1/NCT07203053/registered